Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus;Topische cannabinoidagonisten. Eine effektive, neue möglichkeit zur behandlung von chronischem pruritus

Hautarzt

Volumn 57, Issue 9, 2006, Pages 801-807

  Stander S ^a   Reinhardt, H W ^b   Luger, T A ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b Stiefel Laboratorium GmbH   (Germany)

Author keywords

Cannabinoid receptors; Endocannabinoids; Lichen simplex; Prurigo; Pruritus

Indexed keywords

CANNABINOID RECEPTOR AGONIST;

ABSENCE OF SIDE EFFECTS; ARTICLE; BURNING SENSATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTACT DERMATITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG TOLERABILITY; HUMAN; NEURODERMATITIS; PRURIGO; PRURITUS;

ADMINISTRATION, TOPICAL; ADULT; AGED; AGED, 80 AND OVER; CANNABINOIDS; CHRONIC DISEASE; FEASIBILITY STUDIES; HUMANS; MALE; MIDDLE AGED; PALMITIC ACIDS; PRURITUS; TREATMENT OUTCOME;

EID: 33748652898     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-006-1180-1     Document Type: Article

References (20)

1. Berdyshev EV, Boichot E, Germain N et al. (1997) Influence of fatty acid ethanolamides and delta9-tetrahydrocannabinol on cytokine and arachidonate release by mononuclear cells. Eur J Pharmacol 330: 231-240
2. Bouaboula M, Rinaldi M, Carayon P et al. (1993) Cannabinoid-receptor expression in human leukocytes. Eur J Biochem 214: 173-180
3. Devane WA, Dysarz FA III, Johnson MR et al. (1988) Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 34: 605-613
4. Di Marzo V, Bisogno T, De Petrocellis L et al. (1999) Cannabimimetic fatty acid derivatives: the anandamide family and other endocannabinoids. Curr Med Chem 6: 721-744
5. Dvorak M, Watkinson A, McGlone F, Rukwied R (2003) Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 52: 238-245
6. Facci L, Dal Toso R, Romanello S et al. (1995) Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. Proc Natl Acad Sci USA 92: 3376-3380
7. Gallily R, Breuer A, Mechoulam R (2000) 2-Arachidonylglycerol, an endogenous cannabinoid, inhibits tumor necrosis factor-alpha production in murine macrophages, and in mice. Eur J Pharmacol 406: R5-7
8. Kemény L (2005) Comparative study of S236 cream and hydrocortisone 1% in patients with atopic dermatitis. JAAD 52: P68 (Abstr.)
9. Klegeris A, Bissonnette CJ, McGeer PL (2003) Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. Br J Pharmacol 139: 775-786
10. Lambert DM, Vandevoorde S, Jonsson KO, Fowler CJ (2002) The palmitoylethanolamide family: a new class of anti-inflammatory agents? Curr Med Chem 9: 663-674
11. Matsuda LA (1997) Molecular aspects of cannabinoid receptors. Crit Rev Neurobiol 11: 143-166
12. Munro S, Thomas KL, Abu-Shaar M (1993) Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65
13. Pertwee RG (1999) Evidence for the presence of CB1 cannabinoid receptors on peripheral neurones and for the existence of neuronal non-CB1 cannabinoid receptors. Life Sci 65: 597-605
14. Ralevic V (2003) Cannabinoid modulation of peripheral autonomic and sensory neurotransmission. Eur J Pharmacol 472: 1-21
15. Ralevic V, Kendall DA (2001) Cannabinoid inhibition of capsaicin-sensitive sensory neurotransmission in the rat mesenteric arterial bed. Eur J Pharmacol 418: 117-125
16. Ross RA, Coutts AA, McFarlane SM et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40: 221-32
17. Rukwied R, Watkinson A, McGlone F, Dvorak M (2003) Cannabinoid agonists attenuate capsaicini-nduced responses in human skin. Pain 102: 283-288
18. Ständer S, Schmelz M, Metze D et al. (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38: 177-188
19. Ständer S, Weisshaar E, Steinhoff M, Luger TA, Metze D (2003) Pruritus - Pathophysiologie, Klinik und Therapie - Eine Übersicht. JDDG 1: 105-118
20. Szepietowski JC, Szepietowski T, Reich A (2005) Efficacy and local tolerance of S236 Cream in patients undergoing maintenance hemodialysis suffering from uremic pruritus. JAAD 52: P69 (Abstr.)